Clinical Trial Update: Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Vacc-C5 with adjuvants GM-CSF or Alhydrogel in HIV-1-infected subjects on ART has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Alhydrogel (Aluminum hydroxide adjuvant)
• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Vacc-C5 (Vacc-C5 vaccine)

Snippet

Sponsor: Bionor Immuno AS | Conditions: HIV-1 Infection | Phase 1, Phase 2 | Status: COMPLETED